Examining visual field defects in the paediatric population exposed to vigabatrin
Related Experiment Video
Updated: Aug 29, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
Published on: May 25, 2020
1Neurosciences Research Institute, Aston University, Birmingham, UK. emma.spencer@quintiles.com
Insights
Vigabatrin, an antiepileptic drug, can cause visual field loss in children. A new field-specific visual evoked potential (VEP) test is effective for detecting this vision defect in pediatric patients.
Area of Science:
- Ophthalmology
- Neurology
- Pediatrics
Background:
- Vigabatrin is an effective antiepileptic drug for infantile spasms.
- Vigabatrin use is associated with peripheral visual field loss.
- Assessing visual field function in children is challenging.
Purpose of the Study:
- To evaluate a field-specific visual evoked potential (VEP) for detecting vigabatrin-induced visual field defects in children.
- To compare the VEP method with electroretinography (ERG) and perimetry in a pediatric population.
Main Methods:
- A field-specific VEP using central and peripheral stimuli was developed.
- Thirty-nine children (3-15 years) treated with vigabatrin were included.
- VEP, ERG, and perimetry were performed where feasible.
Main Results:
- The field-specific VEP showed 75% sensitivity and 85.7% specificity in detecting visual field abnormalities.
- The VEP correctly identified 3/4 abnormal perimetry results and 6/7 normal perimetry results.
- 30-Hz flicker amplitude in ERG showed 75% sensitivity and 71% specificity.
Conclusions:
- The field-specific VEP is a well-tolerated and reliable method for assessing vigabatrin-associated visual field loss in children.
- The prevalence of this visual defect in children appears similar to that in adults.
- VEP offers a viable alternative for visual field assessment in pediatric patients unable to complete perimetry.
Abstract:
The antiepileptic drug, vigabatrin, has been linked to a specific pattern of visual field loss. The majority of studies have not included the paediatric population due to difficulties assessing visual field function. This is a particular problem as vigabatrin is effective against infantile spasms. A field-specific visual evoked potential was developed which consisted of a central stimulus (0-5 degrees radius) and a peripheral stimulus (30-60 degrees radius). Both stimuli consist of black and white checks which increase in size with eccentricity. Responses are recorded from occipital electrodes O2 and O1 referred to frontal electrode Fz. Electroretinograms and perimetry was performed were possible as a comparison. Thirty-nine children with epilepsy treated with vigabatrin aged from 3 to 15 years were included in the study; 35/39 children complied with the field-specific VEP, 26/39 complied with the ERG and 11/39 performed perimetry. Of these results, 18 children had normal ERG responses and eight had abnormal response. Visual field testing revealed four children had abnormal and seven had abnormal visual field results. The Field-specific VEP identified three of four abnormal perimetry results and six of seven normal perimetry results, giving a sensitivity of 75% and a specificity of 85.7%. When comparing perimetry results with the ERG parameters only the 30-Hz flicker amplitude, with a cut-off amplitude below 70 microV, gave a useful sensitivity of 75% and a specificity of 71%. The field-specific VEP is a useful alternative method that is both well tolerated by young children and gives a reliable indication of likely peripheral visual field loss associated with vigabatrin. The defect appears to have a similar prevalence in children as it does in adults.

